Rheumatoid arthritis (RA) is an inflammatory disease associated with intense angiogenesis and vascular expression of integrin αvβ3. Intra-articular administration of a cyclic peptide antagonist of integrin αvβ3 to rabbits with antigen-induced arthritis early in disease resulted in inhibition of synovial angiogenesis and reduced synovial cell infiltrate, pannus formation, and cartilage erosions. These effects were not associated with lymphopenia or impairment of leukocyte function. Furthermore, when administered in chronic, preexisting disease, the αvβ3 antagonist effectively diminished arthritis severity and was associated with a quantitative increase in apoptosis of the angiogenic blood vessels. Therefore, angiogenesis appears to be a central factor in the initiation and persistence of arthritic disease, and antagonists of integrin αvβ3 may represent a novel therapeutic strategy for RA.
Introduction
The rheumatoid arthritic joint is characterized by massive synovial proliferation and changes in synovial architecture resulting in interdigitating folds of tissue,termed pannus. The formation of active inflamed pannus is thought to be central to erosive disease and resulting joint destruction (1) . Angiogenesis, the formation of new blood vessels, is one of the earliest histopathologic findings in rheumatoid arthritis (RA) and appears to be required for pannus development (2) . This neovascularization is thought not only to maintain the chronic architectural changes via delivery of required blood-borne elements to the pannus but also to play an active role in inflammation as a source of both cytokine and protease activity (3) . The expanded vascularbed volume resulting from angiogenesis may provide increased access for inflammatory cells to infiltrate the synovium (4) . Although the factors specifically promoting angiogenesis in RA have not been identified, both synovial tissue and fluid are enriched in angiogenesis-promoting molecules. These include cytokines, such as basic fibroblast growth factor (bFGF) (5), interleukin-8, and vascular endothelial growth factor, and soluble adhesion molecules, such as vascular cell adhesion molecule and Eselectin (6) . Interestingly, many of the available treatments for RA have been shown to possess some degree of antiangiogenic activity (7) (8) (9) . In fact, treatments that suppress the angiogenic process may favorably impact disease course, as suggested by studies in an adjuvant-induced model of arthritis (10) .
We have demonstrated previously that integrin αvβ3 is both a marker and crucial effector for blood vessels undergoing angiogenesis (11, 12) . Blockade of this integrin by either antibody or peptide antagonists induces apoptosis of angiogenic blood vessels in cytokine and tumor models of angiogenesis (11) (12) (13) . In agreement with previous immunohistochemical studies (14, 15) , we found that synovial blood vessels from RA patients show increased expression of integrin αvβ3. These observations prompted the current study, in which treatment directed against vascular integrin αvβ3 was assessed for its impact on arthritic disease in a rabbit model of RA.
In this report, we demonstrate that intra-articular administration of a cyclic peptide antagonist of αvβ3 in bFGF-augmented antigen-induced arthritis (AIA) was associated with a quantitative increase in vascular apoptosis leading to the inhibition of synovial angiogenesis, as well as a reduction in joint swelling, synovial infiltrate, and pannus formation, in both early and well-established arthritis. Importantly, the αvβ3 antagonist provided significant protection against the development of cartilage erosions. These results substantiate the development of αvβ3 antagonists for future clinical trials in RA.
Methods
Materials. Ovalbumin (OVA), Freund's complete and incomplete adjuvants, and bovine type II collagen were from Sigma Chemical Co. (St. Louis, Missouri, USA). SDS (Bio-Rad Life Science Research, Hercules, California, USA), sodium chromate (Amersham Life Sciences, Arlington Heights, Illinois, USA), and Percoll (Pharmacia Biotech, Uppsala, Sweden) were purchased from suppliers as indicated. Goat anti-human von Willebrand factor (vWf) affinity-purified antibody (Enzyme Research Laboratories, South Bend, Indiana, USA) was used as a blood ves-sel marker. Monoclonal antibody (MAB) LM609 directed against integrin αvβ3 (16) was produced and purified from the hybridoma. Fluorescein-conjugated, affinity-purified donkey anti-goat IgG and rhodamine-conjugated, affinity-purified donkey anti-mouse IgG were obtained from Jackson ImmunoResearch Laboratories (West Grove, Pennsylvania, USA). Recombinant bFGF was graciously supplied by J. Abraham (Scios Inc., Mountain View, California, USA). Cyclic peptides (17) Establishment of AIA. All experiments were performed in strict accordance with the guidelines of The Scripps Research Institute Department of Animal Resources. Arthritis was induced as described previously (18) . Briefly, male New Zealand White rabbits (2 kg; Western Oregon Rabbit Co., Philomath, Oregon, USA) were immunized in multiple subcutaneous sites with a total of 1 ml OVA (20 mg/ml) in Freund's complete adjuvant and boosted 2 weeks later with 0.6 ml OVA (20 mg/ml) in Freund's incomplete adjuvant. Arthritis was induced 1 week later by bilateral knee intra-articular injection of 0.5 ml OVA/PBS (20 mg/ml) with or without recombinant bFGF (6 µg/ml). Animals were immobilized by predosing with 2 mg acepromazine, followed by inhalation of 2.5% halothane/1.0 l min −1 nitrous oxide/1.0 l min −1 oxygen anesthesia. Analgesia was provided with buprenorphine hydrochloride (Reckitt and Colman Pharmaceuticals Inc., Richmond, Virginia, USA), 0.2 ml twice daily.
Treatment protocol. OVA-immunized rabbits were randomized, based on ELISA-determined OVA-antibody titers (see ref. 22) , into groups treated with the αvβ3 antagonist peptide (EMD 66203) or control peptide (EMD 69601) before arthritis induction with OVA/bFGF. Beginning 24 h after arthritis induction, and again on days 7, 14, and 21, animals were anesthetized and peptides administered by intra-articular injection (0.5 ml/knee, 2 mg/ml). Rabbits were harvested on day 28. To assess the effect of αvβ3 antagonist treatment on chronic disease, rabbits with AIA were randomized (based on day 1 and day 7 knee diameter) into a control group (no treatment) or treatment with the αvβ3 antagonist (0.5 ml/knee, 2 mg/ml administered on days 14, 16, 18, 21, and 25) .
Assessment of arthritis. Joint swelling, defined as increase in extended knee diameter from normal, was measured with dial calipers (0.254 mm; Fisher Scientific, Tustin, California, USA). All assessments were performed by a blinded observer. Immunofluorescence was performed as described previously (12) Results of early treatment are pooled data from separate experiments expressed as mean ± SE. Statistical evaluation was performed with ANOVA or Student's t test (JMP IN software; Duxbury Press, San Francisco, California, USA), with P < 0.05 considered significant.
Characterization of antagonist activity. Migration toward RA synovial fluid (1:10 in DMEM) in the presence or absence of peptide antagonists (1 mg/ml) was assessed in transwell assays, using purified radiolabeled AIA rabbit leukocytes as reported previously (20) . The relative affinity of the individual antagonists for isolated integrins was determined via soluble ligandbinding studies, as published (21) .
Results
The angiogenic growth factor bFGF enhances arthritic disease. To assess the effect of increased angiogenesis on arthritis development, the proangiogenic cytokine bFGF was added to antigen during arthritis induction. Recent evidence has shown bFGF to be upregulated and localized to the pannus-cartilage interface in RA tissues (5) . The inclusion of bFGF in this model resulted in more consistent and accelerated arthritis than with antigen alone, characterized by greater joint swelling (Fig. 1a) , increased pannus formation (Fig. 1b) , and more frequent erosive disease (Fig. 1c ). These results demonstrate that bFGF, an angiogenic growth factor, can exacerbate arthritis.
Integrin αvβ3 is selectively expressed on synovial blood vessels in AIA and in human RA. The rabbit AIA model resembles human RA in several important aspects, including histopathology and its response to therapeutic agents (18, 22) . Rabbit AIA displays marked neovascularization accompanied by synovial growth and subsynovial inflammatory infiltrate (Fig. 2a) . Notably, αvβ3 staining in AIA is restricted to synovial blood vessels (Fig. 2b) , as in human RA, which is indicative of ongoing angiogenesis; blood vessels in sections from normal, nonarthritic synovium express little or no αvβ3 (data not shown). The earliest invasive blood vessels, although positive for αvβ3, do not stain for vWf (Fig 2b, arrows) , reflecting the fact that vWf is a marker of differentiated endothelium (23) . As vessels mature, αvβ3 is lost (24) . The hyperproliferative synovial lining and subsynovial tissue also contain numerous fibroblasts and macrophages (Fig. 2a) (1) . In contrast to cutaneous wound fibroblasts, which express integrin αvβ3 (25), little or no expression of this integrin was found on synovial fibroblasts (Fig. 2b ), in agreement with previous studies (14, 15, 26, 27) . With respect to synovial macrophages, αvβ3 expression was found to be restricted to osteoclasts and was not present in other monocyte/macrophage-derived cells (28) .
Figure 3
Joint swelling is reduced after αvβ3 antagonist administration in AIA. (a) Rabbits with AIA were treated with bilateral intra-articular αvβ3 antagonist (EMD 66203; 0.5 ml, 2 mg/ml) or control peptide (EMD 69601) beginning 24 h after arthritis onset, and weekly thereafter for 4 weeks (arrows). Joint swelling, defined as the increase in knee diameter from normal (nonarthritic), was significantly reduced by the αvβ3 antagonist (days 14-28, P < 0.05, ANOVA) compared with control peptide. (b) Periarticular vascularization (arrowheads) was prominent in control-treated AIA compared with antagonist-treated groups.
Figure 4
Synovial vascularity is decreased after αvβ3 antagonist treatment. (a) Cryosections of the infrapatellar tissue obtained 28 days after arthritis onset in animals treated with the αvβ3 antagonist or control peptide (days 1, 7, 14, and 21) were stained for vWf as a marker of blood vessels, detected with FITC-labeled secondary antibody, and were digitally imaged (×200). (b) The relative increase in area of fluorescent pixels per field vs. normal was computed to determine the angiogenic index as described in Methods. Synovial neovascularization was significantly inhibited by the αvβ3 antagonist (P < 0.050, Student's t test). Data are expressed as mean ± SE (n = 20).
Synovial neovascularization is inhibited by an
or peptide antagonists successfully inhibits neovascularization in cytokine and tumor models of angiogenesis in avian, murine, rabbit, and human tissues (11) (12) (13) . To evaluate whether blockade of integrin αvβ3 could impact arthritis-associated angiogenesis, rabbits with AIA were treated intra-articularly 24 hours after arthritis onset and weekly thereafter for four weeks with the αvβ3 antagonist EMD 66203. This treatment resulted in a modest yet significant (P < 0.05) decrease in joint swelling compared with that in animals treated with the control peptide, EMD 69601 (Fig. 3a) . Initial examination of knee joints revealed obvious periarticular vascularization in the control-treated animals (Fig. 3b) . Cryosections of the infrapatellar fat-pad were examined with anti-vWf as a blood vessel marker. Tissues from rabbits treated with the αvβ3 integrin antagonist displayed considerably fewer blood vessels than tissues from control-treated rabbits (Fig. 4a) . Blinded computer analysis of digital images revealed a 48% decrease in synovial neovascularization in αvβ3 antagonist-treated animals ( Fig. 4b) (P < 0.01).
To determine whether the αvβ3 antagonist was targeted to the vasculature in the arthritic synovium, we evaluated the distribution of a fluorescent-labeled form of this peptide, EMD 80838. Twenty-four hours after intra-articular injection, the fluorescent-conjugated αvβ3-binding peptide selectively localized to microvessels within the arthritic synovium, as determined by confocal microscopy (Fig. 5 ). These studies demonstrate that the αvβ3 antagonist targets synovial blood vessels in this model and inhibits angiogenesis in the arthritic synovium.
Animals treated with the αvβ3 antagonist show reduced synovial infiltrate. To evaluate whether the observed angiogenesis inhibition in αvβ3 antagonist-treated animals was associated with a change in arthritis, several disease parameters were examined. Angiogenesis inhibition has been postulated to limit accessibility of the tissue to leukocytes (3); therefore, we first examined whether there was any decrease in the degree of synovial inflammatory infiltrate in animals treated with the antiangiogenic αvβ3 antagonist. Histological examination of the infrapatellar fat-pad revealed that treatment with the αvβ3 antagonist resulted in significantly fewer cells infiltrating the synovium (Fig. 6a) . Computerized cell counting of digital images of these sections demonstrated a 39% reduction in synovial cellular infiltrate (Fig. 6b) (P < 0.05). Since only a small fraction of peripheral lymphocytes (1%-2%) express integrin αvβ3 (29), it is unlikely that the reduction in cellular infiltrate was due to leukocyte integrin inhibition. In fact, chemotaxis of AIA peripheral blood mononuclear cells (PBMCs) and polymorphonuclear neutrophils (PMNs) toward RA synovial fluid was not influenced by either the αvβ3-directed peptide or the control peptide on collagen (Fig. 6c) or fibronectin (data not shown). No leukopenia or other sign of hematologic or marrow toxicity was observed after treatment in either group (Table 1) . Immunohistochemical analysis revealed no difference in the degree of colocalization between apoptotic cells and leukocytes, as determined by TUNEL and KEN-11 (anti-LFA-1) costaining studies between control and αvβ3 antagonist-treated rabbits (data not shown). Thus, the reduced synovial infiltrate observed in the αvβ3 antagonist-treated AIA synovium does not appear to result from direct effects of this compound on leukocyte number or migration.
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Figure 5
Fluorescent integrin antagonist colocalizes with synovial angiogenic microvessels. An FITC-conjugated αvβ3 antagonist peptide, EMD 80838 (cyclic-Arg-Gly-Asp-D-Phe-Lys-[fluoresceincarboxylic acid]; 0.5 mg/500 µl), was injected intra-articularly in rabbits with AIA. After 24 h, cryostat sections (5 µm) of synovial tissue were examined by confocal microscopy for the presence of peptide (green). Blood vessels were identified by antisera to vWF as detected with TRITC-labeled secondary antibody (red). Colocalization of αvβ3 antagonist is observed on angiogenic microvessels after signal merge (yellow), but not with mature vWF + vessels (×630). TRITC, tetrarhodamine isothiocyanate. The αvβ3 antagonist protects against erosive disease. Since pannus formation is thought to initiate progression to erosive disease (1), the effect of the αvβ3 antagonist on the development of pannus was examined. In control-treated animals, extensive pannus formation covering much of the femoral articular cartilage surface was observed, whereas treatment with the αvβ3 antagonist resulted in significant reduction of pannus development (P < 0.05) (Fig. 7a) . The αvβ3 antagonist also significantly blocked the development of cartilage erosions. Gross erosions were present in 70% (14 of Vascular integrin αvβ3 is the preferred target in AIA. Recent studies suggest that both integrin αvβ3 and integrin αvβ5 can play a role in angiogenesis (30) . Therefore, we compared the antiarthritic effects of the cyclic peptide with αvβ3 selectivity, EMD 66203, with that of a peptide with higher αvβ5-binding activity, EMD 85189. Notably, αvβ5 is also highly expressed on synovial fibroblasts and macrophages (14, 27) . The peptide antagonist with greatest selectivity for αvβ3 demonstrated strongest inhibition of pannus development and erosive disease ( Table 2 ), suggesting that αvβ3 was the primary therapeutic target in this model.
Chronic arthritis is ameliorated by the αvβ3 antagonist.
We extended these studies to evaluate the effect of αvβ3 blockade on well-established arthritis. AIA was allowed to progress for two weeks into the chronic phase (18) before the initiation of treatment. Despite the delay, joint swelling was significantly decreased by the αvβ3 antagonist (Fig. 8a) . In this chronic model, treatment with the antagonist produced a significant antiangiogenic effect, with a 64% reduction in the angiogenic index compared with untreated AIA (P < 0.05) (Fig. 8b) , and blockade of αvβ3 was again associated with a marked reduction in the synovial cell infiltrate (P < 0.05) (Fig. 8c) . As observed previously with early administration during acute disease, delayed treatment with the αvβ3 antagonist decreased pannus formation and reduced the incidence of erosive disease compared with controls (Fig. 8, d and e) . From these results, we conclude that angiogenesis contributes to disease severity as well as chronicity, and that an antagonist of integrin αvβ3 is an effective antiarthritic agent in well-established disease.
Synovial vascular apoptosis is associated with αvβ3 antagonist treatment. Previous studies have demonstrated that antagonists of integrin αvβ3 induce apoptosis of angiogenic blood vessels (11) (12) (13) . Therefore, we examined synovial tissues from the chronic arthritis model for the presence of apoptotic cells after treatment with the αvβ3 antagonist. Immunohistochemical detection of apoptosis within AIA synovium demonstrated increased (2.5-fold) TUNEL-positive vascular cells in the αvβ3 antagonist-treated animals (P < 0.01) (Fig. 9 ). These observations suggest that αvβ3 antagonists may inhibit angiogenesis in the arthritic synovium by inducing apoptosis of angiogenic blood vessels.
Discussion
RA has been classified as an angiogenesis-associated disease, based on the finding of extensive neovascularization within the inflamed synovium (3). Clearly, inflammatory cytokines with angiogenic activity can induce or potentiate synovitis (31, 32) . However, it has not been determined whether angiogenesis directly contributes to the arthritic process or whether it is merely a consequence of ongoing inflammation. Evidence is provided in this report that angiogenesis contributes to arthritic disease.
The Journal of Clinical Investigation | January 1999 | Volume 103 | Number 1 51 Table 1 No hematologic toxicity with αvβ3 antagonist treatment Determinations of peptide antagonist IC50 on isolated integrins were performed as described previously (24) . Rabbits with bilateral AIA were treated with intra-articular injection of peptides (2 mg/ml, 500 µl) beginning 24 h after arthritis induction and on days 7, 14, and 21. After 4 weeks, joint swelling, pannus formation, and the presence of macroscopic erosions were evaluated as detailed in Methods. All data are shown as mean ± SE (n = 8 peptides; n = 4 untreated).
Addition of the proangiogenic cytokine bFGF to AIA accelerated and exacerbated arthritis. The inclusion of bFGF in this model was based on the facts that bFGF does not possess the inflammatory properties associated with other angiogenic factors (e.g., interleukin-8 [31] andtumor necrosis factor-α [32] ), bFGF is upregulated and localized to the pannus-cartilage interface in RA tissues (5) , and synovial levels of bFGF in human RA correlate with disease severity (33) . In fact, the addition of bFGF to AIA produced an accelerated and more consistent arthritis compared with arthritis induced with antigen alone (Fig. 1) , without altering the existing expression and selective distribution of integrin αvβ3, as assessed by staining with LM609 (data not shown). Not only did bFGF accelerate arthritis in this model, but a peptide antagonist selective for integrin αvβ3 inhibited angiogenesis and reduced the severity of arthritis. Joint swelling, synovial infiltrate, pannus formation, and the incidence of cartilage erosions were all significantly reduced in animals treated early with this integrin antagonist. Inhibition of neovascularization, as demonstrated in this model, may influence many parameters of disease, including inflammation, protease production, and tissue metabolism (3) . No evidence for a direct role of the αvβ3 antagonist in impairing peripheral leukocyte migration was detected, nor was acute inflammation affected in antagonist-treated animals upon rechallenge with antigen (data not shown).
Integrin αvβ3 was selectively localized to synovial blood vessels in human RA and rabbit AIA, as determined by costaining with LM609 and anti-vWf (Fig. 2b) . The appearance of αvβ3-positive/vWf-negative vessels reflects the fact that vWf is a marker of more mature vessels (23), whereas αvβ3 is present on very early neovessels (34) . In addition, the αvβ3 antagonist localized to microvessels 24 hours after its intra-articular administration in the arthritic synovium, supporting previous findings that this integrin is found primarily on angiogenic blood vessels (11, 34) .
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The Journal of Clinical Investigation | January 1999 | Volume 103 | Number 1 During maturation and differentiation, monocytes/macrophages may express αv integrins (28, 35, 36) , and in fact, antagonists of αvβ3 can influence macrophage-derived osteoclast function (37) , which may contribute to the observed decrease in bone erosions after αvβ3 antagonist treatment. However, functionally mature (αvβ3 + ) osteoclasts are rarely found in the synovium (38) , and it is uncertain that the short-term, intermittent dosing regimen of the αvβ3 antagonist used in this study would be sufficient to impact ongoing osteoclast function. Although the αvβ3-selective cyclic peptide antagonist can impact other αv integrins, it is ineffective against β1 integrin-mediated adhesion (data not shown). Antagonism of integrin β1 with small Arg-Gly-Asp -containing linear peptide fragments of fibronectin induces collagenase expression in synovial fibroblasts, and administration of these peptides may thereby actually increase disease (39) . Although αvβ3 is present in certain fibroblast populations (25) , it was not detected in fibroblasts from synovial tissues in patients with RA (14, 26, 27) .
The integrin antagonist used, although selective for integrin αvβ3, exhibits some activity against the closely related integrin αvβ5 ( Table 2 ). Antagonism of integrin αvβ5 is sufficient to block angiogenesis induced by some cytokines (30) and thus may have contributed to the reduced synovial vascularization observed. However, administration of an antagonist with a higher affinity for integrin αvβ5, which is also expressed on synovial fibroblasts and macrophages (14, 27) , resulted in only minor improvements in arthritis severity ( Table 2 ), suggesting that vascular integrin αvβ3 is the preferred target in inflammatory arthritis.
The results presented in this report provide evidence for a central pathogenic contribution of angiogenic blood vessels to both the induction and maintenance of arthritic disease. Increased neovascularization was clearly and consistently associated with more severe arthritis. Selective αvβ3 blockade effectively inhibited synovial angiogenesis and provided significant protection against the development of cellular infiltrate, pannus formation, and cartilage erosions. In view of the rather selective distribution of integrin αvβ3 on blood vessels in the arthritic synovium (Fig. 2b) (14, 15, (26) (27) (28) , the quantitative increase in endothelial apoptosis after αvβ3 antagonist treatment, and the decreased vascularity observed, angiogenesis inhibition is a likely mechanism by which αvβ3 antagonists ameliorate arthritis. The fact that an αvβ3 antagonist was effective when administered in the chronic AIA model is relevant to future clinical applications. The expression of integrin αvβ3 on synovial blood vessels in human RA presents an opportunity to pursue αvβ3 integrin-directed antiangiogenic therapy for the treatment of RA.
Figure 9
Vascular cell apoptosis is associated with αvβ3 antagonist treatment. (a)Synovium from rabbits in the chronic AIA model were stained with TUNEL immunostaining (red) as an indicator of apoptosis, (arrowheads)and anti-vWF (green) as a marker of blood vessels (×400). (b) Apoptosis associated with blood vessels was detected and quantified blindly as percent blood vessels containing apoptotic cells in 20 fields (×400) per specimen. Apoptosis was increased specifically in the vasculature of arthritic synovium after αvβ3 antagonist treatment (P < 0.01, Student's t test). TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling.
